EGFR and non-small cell lung carcinoma: In the ORIENT-31 study 23, sintilimab+ IBI305+ cisplatin and pemetrexed were generally effective and well tolerated compared to chemotherapy in patients with EGFR-mutated NSCLC who progressed after EGFR-TKI treatment.